OSSTEC EIS

The problem

Osteoarthritis, which causes joints to become painful and stiff, currently affects 15% of the global population over the age of 30. By 2050, nearly 1 billion people are expected to be living with the condition, with knee osteoarthritis cases projected to increase by 75%.

Knee replacement is commonly offered as a treatment. However, the growing number of younger and more active patients undergoing the procedure is placing greater emphasis on implant longevity.

Conventional implants typically rely on bone cement to secure the implant to the bone. Over time, that bond can weaken, causing pain and potentially requiring revision surgery. Implant loosening remains one of the leading causes of knee replacement failure.

The risk of implant loosening is particularly significant in partial knee replacement because there is less bone surface available to secure the implant to. A partial knee replacement preserves more of the patient's natural knee and can offer benefits including a faster recovery, less bone removal and a more natural-feeling result. Yet despite around 50% of patients being suitable candidates, only around 10% receive a partial knee replacement, largely because of fixation and surgical workflow challenges.

OSSTEC’s solution

OSSTEC has spent the last 10+ years developing a solution: ASCENT, a 3D-printed, cementless partial knee implant designed to address both barriers.

3D printing with specialised additives allows OSSTEC to manufacture an implant with a highly porous surface that mimics the structure of natural bone. Rather than relying on cement, it is press-fitted into place so that the patient’s bone can grow into the implant as they recover. This creates biological fixation – a potentially stronger and more durable connection between the implant and the bone.

ASCENT is supplied with OSSTEC's CLARITY instrumentation, which aims to make the procedure more familiar and efficient for surgeons. Management believes this could save up to 15 minutes and $3,400 per case.

Both the implant and procedure have been tested across more than 20 cadaver laboratories in the UK and US. By combining cementless fixation with a streamlined surgical workflow, OSSTEC aims to expand the application of partial knee replacement among both surgeons and patients.

Why invest?

Demand for knee replacement surgery continues to rise as populations age, obesity becomes more prevalent and people remain active for longer. In 2022, 1.85 million knee replacement procedures were performed across OECD countries, up from 1.43 million in 2011. At the same time, more procedures are being performed on younger patients, placing greater emphasis on implant longevity.

With close ties to Imperial College, OSSTEC has spent more than 10 years developing its cementless orthopaedic implant technology, supported by 40+ peer-reviewed publications. Its intellectual property portfolio includes 12 patent filings across five territories and three granted patents.

The Company is now approaching commercialisation. It expects to submit a 510(k) application to the US Food and Drug Administration (FDA) in Q4 2026. The 510(k) pathway allows medical devices to be cleared by demonstrating they are substantially equivalent to an existing approved product and does not typically require large clinical studies. Management hopes to receive FDA clearance in Q1/Q2 2027 – not guaranteed.

OSSTEC has assembled a surgeon faculty across the UK and US that performs more than 2,000 procedures annually and is expected to start using ASCENT following FDA clearance. The Company is also in discussions with eight large orthopaedic companies regarding potential distribution and strategic partnership opportunities.

While ASCENT is its lead product, the underlying biomimetic implant platform could be applied to other orthopaedic implants in future.

The opportunity

OSSTEC is currently seeking to raise £4 million to support regulatory approval and market launch planned in Q1/Q2 2027 – not guaranteed. £3.5 million has been committed by Embryo Ventures, New Wave Ventures, OTIF (formerly Oxford Investment Consultants), Empirical Ventures and SFC Capital – the introducer of this offer. The pre-money valuation is £16.8 million, equivalent to a share price of £8.42.

Wealth Club has been offered a £500k allocation – the minimum investment is £20,616 and you can apply online. Based on the Company’s forecasts, the target return for this private offer is 7x after 3-5 years – high risk and not guaranteed.

OSSTEC plans to launch a new round early next year on receipt of FDA clearance, potentially at a higher valuation – not guaranteed. The Company has already secured an anchor term sheet for £6 million of this new round at a valuation of £24 million – so investors in this current round could potentially participate at a 30% discount to the next round.

As can be expected when investing in an early-stage medical technology business, the potential rewards are significant, but so are the risks. Please carefully read all investment documents prepared by the Company and SFC to form your own view.

This is a single company offer with no diversification. It involves investing in an early-stage business, which is by nature high risk and prone to failure. There is a risk that the capital raised may not be sufficient to achieve the Company’s objectives. You could lose all the amount you invest.

Like all investments available through Wealth Club, it is only for experienced investors happy to make their own investment decisions without advice.

There is no ready market for unlisted EIS shares: they are illiquid and hard to sell and value. There will need to be an exit for you to receive a realised return on your investment. Exits are likely to take considerably longer than the three-year minimum EIS holding period; equally, an exit within three years could impact tax relief.

To claim tax relief, you will need an EIS3 certificate, normally issued once the round closes. This can take several months: please check the deployment timescales carefully. Tax reliefs depend on company maintaining its EIS-qualifying status. Remember, tax rules can change and benefits depend on circumstances.

Before you invest, please carefully read the Information Memorandum which contains further details on the considerable risks – alongside the Wealth Club Risks and Commitments.

Investors in this round will buy shares in OSSTEC Ltd. Shares will be issued at a price of £8.42 per share.

The investment is expected to be EIS-qualifying – not guaranteed. 

Wealth Club Nominees will act as the custodian and administrator of this offer. 

All the services Wealth Club and, where applicable, its subsidiaries provide are governed by the Terms and Conditions of the Wealth Club Services.

Investors will pay an initial charge of 2% deducted from subscription. EIS tax relief will be available on the subscription amount net of the initial charge. There are no ongoing fees. Wealth Club will be entitled to a performance fee on exit.

SFC Capital will also receive a fundraising fee, which it will share with Wealth Club. Please see the Wealth Club Schedule of Charges for more details.

This financial promotion has been communicated and approved by Wealth Club Ltd on 16 October 2026

Wealth Club aims to make it easier for experienced investors to find information on – and apply for – investments. You should base your investment decision on the offer documents and ensure you have read and fully understand them before investing. The information on this webpage is a marketing communication. It is not advice or a personal or research recommendation to buy any of the investments mentioned, nor does it include any opinion as to the present or future value or price of these investments. It does not satisfy legal requirements promoting investment research independence and is thus not subject to prohibitions on dealing ahead of its dissemination.